Sorafenib is the first-line treatment for HCC, and it can inhibit tumor angiogenesis by targeting the RAF-MEK-ERK signaling pathway or blocking the expression of vascular endothelial growth factor receptor (66). This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.